GlassScriptPhysician profile
David J Geidl
NPI 1871774075
$9,711.51
in general payments reported to CMS, 2019-2025
48 companies · $2,861 in 2025
The $2,861 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $350 · 2022: $1,193 · 2023: $3,092 · 2024: $2,216 · 2025: $2,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,122 · Education: $46.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,122.09 |
| Education | $46.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,573.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,360.23 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $924.55 | 2021-2025 | |
| Novo Nordisk INC | $754.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $748.12 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $539.49 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $504.12 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Corium, LLC | $375.64 | 2023-2024 | Azstarys |
| Glaxosmithkline, LLC. | $301.04 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.75 | 2022-2024 | Xifaxan, Trulance |
| Antares Pharma, INC. | $201.49 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $201.39 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $182.60 | 2023-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $142.95 | 2024-2025 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $131.25 | 2023-2025 | Rexulti |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $104.84 | 2023-2024 | Cequr Simplicity |
| Globus Medical, INC. | $102.03 | 2025 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.89 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $88.35 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $86.71 | 2024-2025 | Voquezna |
| Lundbeck LLC | $84.50 | 2023-2025 | Rexulti |
| Halozyme INC | $80.48 | 2023 | |
| Astellas Pharma US INC | $75.11 | 2023-2025 | Veozah |
| Dexcom, INC. | $69.13 | 2024-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $60.20 | 2022 | |
| Exact Sciences Corporation | $57.50 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boston Scientific Corporation | $48.66 | 2023-2025 | Watchman Access System, Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $47.84 | 2021-2022 | |
| Eisai INC. | $47.51 | 2024-2025 | |
| Axsome Therapeutics, INC. | $43.92 | 2025 | Sunosi, Auvelity |
| Alnylam Pharmaceuticals INC. | $43.54 | 2023-2024 | Amvuttra |
| Adlon Therapeutics L.P. | $43.19 | 2021 | |
| Supernus Pharmaceuticals, INC. | $36.58 | 2022 | Xyosted, Tlando |
| Teva Pharmaceuticals USA, INC. | $35.20 | 2023-2024 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $33.41 | 2023 | Xarelto |
| Impel Pharmaceuticals INC. | $32.35 | 2023 | Trudhesa |
| Neos Therapeutics, LP | $30.73 | 2022 | |
| Daiichi Sankyo INC. | $22.90 | 2024 | Injectafer |
| Saluda Medical Americas, INC. | $22.87 | 2025 | Evoke |
| Novartis Pharmaceuticals Corporation | $21.53 | 2023 | |
| Radius Health, INC. | $21.16 | 2025 | Tymlos |
| Tris Pharma INC | $21.01 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.10 | 2021 | |
| Neurelis, INC. | $17.23 | 2024 | Valtoco |
| Vertex Pharmaceuticals Incorporated | $16.17 | 2025 | |
| Sanofi Pasteur INC. | $15.14 | 2023 | |
| Ibsa Pharma INC. | $14.42 | 2022 | |
| Almatica Pharma LLC | $13.32 | 2023 | Gralise, Sertraline Hcl, Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Geidl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.